Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and ...

The companies Moderna, Amylyx Pharmaceuticals, and Braveheart Bio bagged the biggest biotech funding rounds overall in August ...

See why investor confidence in cell and gene therapies now depends on execution and supply chain strategy—not strong science ...

Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up.

Find out what came out of the ESC Congress 2026, from phase 3 successes and failures to earlier-stage programs.

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize a disease target ...

Home to excellent research institutions, a thriving life sciences community, a strong collaborative culture, and a strategic location at the heart of Europe, Ghent is now investing in cutting-edge ...

For decades, cystic fibrosis has remained a relentless, life-limiting disease. But now, the future of cystic fibrosis care could be shifting from symptom management to something far more revolutionary ...

As U.S. budget cuts and freezes push healthcare and biopharma research in the States towards uncertainty, could Europe be the destination that science talent flocks towards? That’s what the European ...